Levetiracetam Accord (Levetiracetam)

Levetiracetam exerts its antiepileptic effect by binding to the synaptic vesicle protein SV2A. This binding modulates neurotransmitter release, reduces calcium‑dependent vesicle exocytosis, and stabilizes neuronal firing, thereby decreasing the hyper‑excitability that leads to seizure activity.

The dosage of Levetiracetam Accord is individualized. A qualified prescriber determines the appropriate dose, infusion rate, and treatment duration based on the patient’s clinical condition, renal function, and response to therapy. Specific dosing regimens are not provided here.

Safety data for levetiracetam during pregnancy and lactation are limited. The medication is classified as pregnancy category unknown. Clinicians must weigh potential benefits against possible risks to the fetus or infant, and discuss these considerations with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers such as carbamazepine or GABA‑enhancers like valproate. It has a relatively low potential for drug‑enzyme interactions, a rapid onset when given intravenously, and a generally favorable tolerability profile compared with many older antiepileptics.

Levetiracetam Accord should be stored at room temperature, below 25 °C. Keep the solution in its original packaging, protect it from direct light, and avoid exposure to moisture. Do not freeze the product; inspect the container for any particulate matter before use.

Levetiracetam Accord is administered by intravenous infusion. The exact infusion rate and duration are determined by the prescribing physician, who may choose a rapid bolus or a slower infusion depending on the clinical scenario and patient tolerance.

Serious adverse events include severe allergic reactions such as anaphylaxis, psychiatric disturbances (including depression, suicidal ideation, or aggression), and hematologic abnormalities like thrombocytopenia or neutropenia. Prompt medical evaluation is required if any of these symptoms emerge during therapy.

Levetiracetam Accord is contraindicated in patients with known hypersensitivity to levetiracetam or any component of the formulation. Caution is advised for individuals with severe renal impairment, as dose adjustment may be required, and for patients with a history of serious psychiatric reactions.